skip to main content, skip to Quick links, or skip to Search

main content

Oncology/Cardiology

Combination of Prednisone, Cobalamin, Lomustine, and Radiation Therapy for Treatment of Feline Gastrointestinal Lymphoblastic Lymphoma (FGLL)

Description:

Feline gastrointestinal (GI) lymphoblastic lymphoma (FGLL) is a debilitating disease of older cats.  Chemotherapy for treatment of FGLL has been used with limited success and long-term survival is uncommon.  Radiation therapy (RT) is used to treat localized lymphoma in humans and in two small studies of cats with lymphoma confined to the intestinal tract treated with RT, clinical signs improved in most cats.

The purpose of this study is to determine whether the addition of abdominal cavity RT to oral chemotherapy (lomustine), daily oral prednisone, and weekly parenteral cobalamin will improve response to therapy, survival times, and quality of life of affected cats.  If the addition of RT improves outcome, this therapy may be adopted as the standard of care for cats with FGLL and may be used to further study the use of RT for lymphocytic lymphoma and inflammatory bowel disease.

Study Design:

Cats will receive 2 doses of RT and 4 doses of chemotherapy as part of the study.  Cats will be expected to return to NC State at weeks 1, 2, 3, 6, 9 and 12 (a total of 6 visits after initial consultation and staging).

Eligibility:

Financial Incentive:

Contact:

Clinical Studies Core at 919.515.2633 or ccmtr_csc@ncsu.edu or NCSU Radiation Oncology Service at 919.513.6690 or vhconcology@ncsu.edu.

 

Page last updated August 12, 2014